Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
BioCryst Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00957996
First received: August 12, 2009
Last updated: January 28, 2015
Last verified: January 2015
  Purpose

This is a Phase 3, open-label, randomized study of the antiviral activity, safety, and tolerability of intravenous Peramivir in hospitalized subjects with confirmed or suspected influenza infection.


Condition Intervention Phase
Seasonal Influenza
Cough
Sore Throat
Nasal Congestion
Myalgia
Headache
Fatigue
Drug: Peramivir
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 3, Open-Label, Randomized Study of the Antiviral Activity, Safety, and Tolerability of Intravenous Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza Infection

Resource links provided by NLM:


Further study details as provided by BioCryst Pharmaceuticals:

Primary Outcome Measures:
  • Change From Baseline in Influenza Virus Titer (48 Hours) [ Time Frame: Baseline and 48 hours ] [ Designated as safety issue: No ]
    The time-weighted change from baseline in log10 tissue culture infective dose50 (TCID50/mL) was calculated on a by-subject basis through 48 hours using the trapezoidal rule with all available data minus the baseline value. Ninety-five percent confidence intervals about the median time-weighted change from baseline were presented for each treatment group.


Secondary Outcome Measures:
  • Change in Influenza Virus Titer, as Measured by Quantitative RT-PCR (log10 vp/mL) [ Time Frame: Baseline, 48, 108, 216 hours ] [ Designated as safety issue: No ]
    The time-weighted change from baseline in viral titer measured by RT-PCR was calculated on a by-subject basis through 216 hours using the trapezoidal rule with all available data minus the baseline value. Ninety-five percent confidence intervals about the median time-weighted change from baseline were presented for each treatment group.

  • Time to Clinical Resolution [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    Time to clinical resolution was the number of hours from initiation of study treatment until 4 of the 5 signs of clinical stability (including both body temperature and transcutaneous oxygen saturation) met resolution criteria that was maintained for at least 24 hours. The median time to clinical resolution and associated 95% confidence interval were estimated for each treatment group using the method of Kaplan-Meier. Subjects who did not achieve clinical resolution were censored at the time of their last assessment.

  • Number of Participants With Clinical Resolution [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    Clinical resolution was defined as normalization of at least 4 of the 5 signs of clinical stability (including both body temperature and transcutaneous oxygen saturation) for at least 24 hours.

  • Time to Alleviation of Symptoms [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    Time to alleviation of symptoms, defined as the time from initiation of study drug until the start of the 24 hour period where all seven symptoms of influenza are recorded as none or mild, was estimated using the method of Kaplan-Meier (adolescents and adults). The 95% confidence interval about the median was presented. Subjects who did not experience alleviation of symptoms were censored at the time of the last non-missing symptom assessment.

  • Time to Resolution of Fever [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    Time to resolution of fever was the number of hours from initiation of study treatment until temperature was ≤37.2°C/≤99°F oral or ≤37.8°C/≤100°F rectal or tympanic for at least 24 hours with no antipyretic medication taken within 4 hours prior to the temperature measurement. Subjects who did not achieve resolution of fever were censored at the time of their last assessment. The 95% confidence interval about the median were presented.

  • Time to Resumption of Usual Activities [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    Subject's ability to perform usual activities as determined from the visual analog scale (scale ranges from 0 to 10 where 0 indicates subject was unable to perform usual activities at all and 10 indicates subject is able to perform all usual activities fully) was summarized by study visit day and treatment group. The median time to resumption of usual daily activities and associated 95% CI was estimated using the method of Kaplan-Meier for adults and adolescents. Subjects who did not return to the pre-study level of performance of usual daily activities were censored at the time of their last non-missing visual analog scale value. A separate analysis was conducted for children.

  • Time to Hospital Discharge [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    Time to hospital discharge, defined as the number of days from initiation of study drug until the subject is discharged from the hospital, was estimated using the method of Kaplan-Meier. The 95% confidence interval about the median was presented. Subjects who were not discharged during the study period were censored at the last study visit. Subjects who died prior to discharge were censored at the longest observed time to discharge.

  • Number of Participants Experiencing Influenza-related Complications [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    Influenza-related complications were defined as the occurrence of sinusitis, otitis, bronchitis and pneumonia as reported on the Influenza-related complications CRF.

  • Number of Participants Admitted to ICU After Initiation of Treatment [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    The number of subjects experiencing ICU admission after initiation of treatment.

  • Duration of Postbaseline ICU Admission (Kaplan-Meier Estimate) [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    The duration of ICU admission after initiation of treatment was estimated by the method of Kaplan-Meier. Subjects who were not discharged from the ICU were censored at the time of their last assessment

  • Survival (Kaplan-Meier Estimates) [ Time Frame: 14 and 28 days ] [ Designated as safety issue: No ]
    Survival was calculated as the number of days from initiation of study drug until death or last contact. Overall survival was estimated by the method of Kaplan-Meier; 95% confidence intervals for 14- and 28-day survival were presented by treatment group. Subjects who had not died were censored at the date of last contact.


Other Outcome Measures:
  • Number of Participants Who Required More Than 5 Days of Peramivir Treatment [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    The number of subjects who continued more than 5 days were as reported on the Continuation of Treatment CRF page.


Enrollment: 234
Study Start Date: October 2009
Study Completion Date: August 2011
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Peramivir 300 mg
Peramivir 300 mg twice daily
Drug: Peramivir
300 mg twice daily
Experimental: Peramivir 600 mg
Peramivir 600 mg once daily
Drug: Peramivir
600 mg once daily

  Eligibility

Ages Eligible for Study:   6 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and non-pregnant female subjects 6 years of age or older.
  • Able to provide written informed consent, or for whom written consent may be provided by a parent guardian or legally authorized representative, unless consent provided by a parent, guardian or legally authorized representative is not consistent with applicable local or ethical procedures, directives and /or guidelines.
  • Presence of clinical signs and/or symptoms consistent with an acute illness compatible with influenza infection; a measured temperature of ≥ 38.0°C (100.4°F) oral, or ≥ 38.6°C (101.4°F) rectal or tympanic and recent onset of at least one of the following: rhinorrhea or nasal congestion, sore throat or cough. Measured temperature can include fever meeting the above criteria as reported by the subject or their parent, guardian or legally authorized representative in the 24 hours prior to Screening. The requirement for fever is waived for any subject with influenza infection already confirmed by laboratory tests (including Rapid Antigen Tests).
  • Confirmation of influenza A or B infection in the local community by one of the following means:
  • the institution's local laboratory,
  • the local public health system
  • the national public health system
  • a laboratory of a recognized national or multinational influenza surveillance scheme.
  • Severity of illness requiring or anticipated to require in-hospital care.

Exclusion Criteria:

  • Subjects who have been hospitalized for greater than 24 hours (not including time spent in the emergency department).Blood platelet count of < 20 x 109/L.
  • Serum bilirubin > 6 mg/dL at time of Screening evaluation.
  • Serum ALT or AST > 5 X upper limit of normal at time of Screening evaluation.
  • Serum creatinine > 5.0 mg/dL at time of Screening evaluation.
  • Subjects who require peritoneal dialysis or hemofiltration.
  • Altered neurologic status as defined by a Glasgow Coma Score of ≤ 9, unless medically induced.
  • Females who are pregnant (positive urine or serum pregnancy test at Screening evaluation) or breastfeeding.
  • Actively undergoing systemic chemotherapy or radiotherapy treatment for a malignancy. (Subjects who have completed treatment 30 days prior to enrollment are allowed to enroll in the study. Hormone treatment for cancer is also acceptable).
  • Prior hematopoietic stem cell transplantation or solid organ transplant during the previous 4 months.
  • HIV infection with a known CD4 count < 200 cells/ mm3 unless on a stable highly active antiretroviral (HAART) regimen for at least 6 months.
  • Presence of a preexisting chronic infection that is undergoing or requiring medical therapy (eg, tuberculosis). (Subjects with chronic osteomyelitis or hepatitis B or C not requiring treatment are not excluded).
  • Presence of any preexisting illness that, in the opinion of the Investigator, would place the subject at an unreasonably increased risk through participation in this study.
  • Participation as a subject in any study of an experimental treatment for any condition within the 30 days prior to the time of the Screening evaluation.
  • Subjects diagnosed with cystic fibrosis.
  • Subjects with confirmed clinical evidence of acute non-influenzal infection at the time of Screening.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00957996

  Show 110 Study Locations
Sponsors and Collaborators
BioCryst Pharmaceuticals
  More Information

No publications provided by BioCryst Pharmaceuticals

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: BioCryst Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00957996     History of Changes
Other Study ID Numbers: BCX1812-303, HHS 0100200700032C
Study First Received: August 12, 2009
Results First Received: January 16, 2015
Last Updated: January 28, 2015
Health Authority: United States: Food and Drug Administration
Canada: Health Canada
Mexico: Ministry of Health
Australia: Human Research Ethics Committee
New Zealand: Ministry of Health

Keywords provided by BioCryst Pharmaceuticals:
influenza
hospitalized
flu
antiviral

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Respiratory Tract Diseases
Respiratory Tract Infections
Virus Diseases

ClinicalTrials.gov processed this record on August 30, 2015